肿瘤细胞治疗研究
FRONTIER PAPERS
Baiting-enhanced extravasation of lipid nanoparticles for targeted co-delivery of decitabine and siTNF-α to the bone marrow niche in leukemia therapy.
急性髓系白血病（AML）仍然是一种致命性恶性肿瘤，由于药物生物利用度有限以及保护性骨髓微环境内的治疗耐药性，其预后较差。
Engineering CLL-1 CAR-NK cells via mRNA-LNP for potent antitumor activity and reversal of HLA-E-mediated resistance in acute myeloid leukemia.
瞬时、非整合的 mRNA LNP 转染的 CLL-1 CAR-NK 细胞为 MDR AML 提供了一种安全有效的策略。
Therapeutic ecology of the fiber-microbiota-barrier axis in leukemia: resilience, immune recovery and pharmacomicrobiomics.
白血病诊疗是生态系统压力下的一项临床实验。
Biomimetic universal CAR-mesenchymal stem cell nanohybrids for anti-tumor therapy.
值得注意的是，它实现了92.7%的高肿瘤抑制率，并有效诱导巨噬细胞向抗肿瘤的M1型极化。
The evolving landscape of regulatory T cells in leukemia: from mechanisms to advanced immunotherapeutic strategies.
血液系统恶性肿瘤中的肿瘤微环境（TME）构成了一个动态生态系统，支持白血病发生、治疗耐药和免疫逃逸。
The mechanisms and countermeasures for CAR-T cell expansion and persistence deficiency.
嵌合抗原受体（CAR）T 细胞疗法已成为血液系统恶性肿瘤，尤其是 B 细胞恶性肿瘤的开创性治疗。
Mapping the Global Clinical Trial Landscape of Chimeric Antigen Receptor T-Cell Therapy for Chronic Lymphocytic Leukemia: Current Status and Future Pe
Valproic acid increases CAR T cell cytotoxicity against acute myeloid leukemia.
CD123和CLL-1是AML CAR-T细胞治疗的有前景的靶点。
First-in-human phase I study of CLL-1 CAR-T cells in adults with relapsed/refractory acute myeloid leukemia.
本研究首次证明 CLL-1 CAR-T 细胞治疗在成人复发/难治性急性髓系白血病中具有积极的疗效和可耐受的安全性。
Gp350-anchored extracellular vesicles: promising vehicles for delivering therapeutic drugs of B cell malignancies.
我们的发现提示，载药 RBC-EVs/gp350 Etp 或可用于 CD21+ B 细胞恶性肿瘤的治疗。
MEMBER ACCOUNT
登录成功会直接打开下一页。
